TAVI for Pure Aortic Regurgitation FIH Transfemoral Case

Jian Ye, MD, FRCSC

Clinical Professor of Surgery St. Paul's Hospital and Vancouver General Hospital University of British Columbia, Vancouver, Canada

TCTAP, Seoul April 28-30, 2019



Centre for Heart Valve Innovation St. Paul's Hospital, Vancouver






Disclosure Statement of Financial Interest


Consultant:

- Edwards Lifesciences
- JC Medical Inc.


Al and aortic root



Valves used for Al





Problems with most THVs in non-calcified Al patients






Designed for both AS and AI






Approved by CFDA in April 2017


J-Valve Clinical Trial: 2 Year Outcome









18 Fr.



FIH TF J-Valve implantation for pure AI






FIH TF J-Valve implantation for pure AI

St. Paul's J-Valve TF Case Dr. Webb and Dr. Ye 08 FEB 2019







Excellent 30 days and 2-year outcomes of TAVI with TA J-Valve system have been demonstrated in pure AI patients.

J-Valve system is now suitable for transfemoral, transaxillary and transapical approaches.

